PIONEER metastatic Hormone-Sensitive Prostate Cancer treatment characterization
=============

<img src="https://img.shields.io/badge/Study%20Status-Started-blue.svg" alt="Study Status: Started">

- Analytics use case(s): **Characterization**
- Study type: **Clinical Application**
- Tags: **cancer**
- Study lead: **Juan-Gomez Rivas**
- Study lead forums tag: **[bdemeulder](https://forums.ohdsi.org/u/bdemeulder)**
- Study start date: **October 31, 2022**
- Study end date: **-**
- Protocol: **-**
- Publications: **-**
- Results explorer: **-**

The aim of this study is to characterize the metastatic Hormone-Sensitive Prostate Cancer (mHSPC) patients and their treatment plans. The impact of choice of medications on the clinical outcomes (progression, death) will be assessed.

This study is undertaken by the 2022 prostate cancer studyathon of the [IMI PIONEER](https://prostate-pioneer.eu) project.
